AstraZeneca to withdraw Imfinzi U.S. indication for advanced bladder cancer

By

By Reuters Staff

(Reuters) - AstraZeneca will voluntarily withdraw the use of its cancer drug Imfinzi to treat advanced bladder cancer in the United States after it failed to meet post-approval requirements, the Anglo-Swedish drugmaker said on Monday.

Imfinzi, mainly a lung cancer treatment, was granted accelerated approval for the bladder cancer indication in 2017, and the withdrawal does not impact markets outside the United States, the company said.

The treatment failed the main goal of a late-state trial last year and the decision was based in consultation with U.S. authorities, the company said.

"While the withdrawal in previously treated metastatic bladder cancer is disappointing, we respect the principles FDA set out when the accelerated approval pathway was founded," Dave Fredrickson, executive vice president of the company's oncology business division, said in a statement.

Imfinzi belongs to the immunotherapy class of treatments that boost the body's own defences to fight cancer.

AstraZeneca also said other U.S. indications for the drug, which brought in $2.04 billion in global revenue last year, were not affected by the withdrawal, adding that it was notifying healthcare providers of the update.

Related Articles

Photoselective vaporization safely alleviates refractory LUTS in prostate cancer patients

By Matthew Phelan NEW YORK (Reuters Health) - Photoselective vaporization of the prostate can provide relief from refractory lower-urinary-tract symptoms (LUTS) resulting from benign prostatic Read More »

No benefit of dose-intensified salvage radiation for prostate-cancer recurrence

By Megan Brooks NEW YORK (Reuters Health) - Dose-intensified salvage radiotherapy is not superior to conventional dose salvage RT and is associated with increased late rectal toxicity in patients with Read More »

Adjuvant nivolumab prolongs disease-free survival in high-risk urothelial carcinoma

By Megan Brooks NEW YORK (Reuters Health) - Adjuvant treatment with the immune-checkpoint inhibitor nivolumab helped patients with high-risk muscle-invasive urothelial carcinoma (MIUC) live longer Read More »


© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information